Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) for mental health conditions, has announced the completion of patient enrollment in its Phase 3 APPROACH study. This pivotal trial evaluates HLP003 as an adjunctive treatment for major depressive disorder (MDD), and the company anticipates topline data in the fourth quarter of 2026. The announcement came as part of the company's business highlights and financial results for the quarter ended June 30, 2026.
The APPROACH study is part of the PARADIGM program, which also includes the EMBRACE trial, currently enrolling participants, and the EXTEND long-term safety study, which is ongoing. These trials are designed to assess the efficacy and safety of HLP003, a proprietary NSA that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The completion of enrollment in APPROACH is a critical milestone, bringing the company closer to potentially addressing the significant unmet need in MDD, where many patients do not achieve adequate response with existing treatments.
In addition to the progress in the HLP003 program, Helus Pharma is advancing HLP004 for generalized anxiety disorder (GAD). Following Phase 2 results that demonstrated a statistically significant and clinically meaningful improvement from baseline, the company expects to finalize the design of the next study by the end of the third quarter of 2026. This underscores the company's commitment to expanding its pipeline of novel therapies for mental health conditions.
Financially, Helus Pharma reported cash and cash equivalents of $166.4 million as of June 30, 2026, providing a solid runway to support ongoing clinical development. The company reported a net loss of $47.8 million for the quarter, up from $24.6 million in the same period last year, reflecting increased investment in the Phase 3 trials. Cash-based operating expenses rose to $37.5 million from $23.9 million, primarily due to the advancement of the APPROACH, EMBRACE, and EXTEND studies.
Looking ahead, Helus Pharma is also advancing HLP005, another investigational NSA, toward candidate selection, with a viable development candidate anticipated in the second half of 2027. This early-stage program highlights the company's broader research efforts in the NSA space.
The company's focus on NSAs is driven by the hypothesis that these molecules can activate serotonin pathways to promote neuroplasticity, offering a potential new mechanism for treating depression and anxiety. With the completion of enrollment in APPROACH, Helus Pharma is one step closer to delivering a much-needed new option for patients with MDD. The upcoming topline data in Q4 2026 will be a key catalyst for the company and the field.
For more information on the full press release, visit https://ibn.fm/yfpOW.
